Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients

被引：34
|
作者：
Reardon, David A.
Nayak, Lakshmi
Peters, Katherine B.
Clarke, Jennifer Leigh
Jordan, Justin T.
De Groot, John Frederick
Nghiemphu, Phioanh Leia
Kaley, Thomas Joseph
Colman, Howard
Gaffey, Sarah C.
Caruso, Victoria
Debruyne, Myriam Bednarek
Bhavsar, Chinmay
Molinaro, Annette M.
Smith, Timothy
Severgnini, Mariano
Wen, Patrick Y.
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Harvard Med Sch, Boston, MA USA
[3] Duke Univ, Med Ctr, Durham, NC USA
[4] Univ Calif San Francisco, San Francisco, CA USA
[5] Massachusetts Gen Hosp, Boston, MA USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Neuro Oncol, Houston, TX USA
[7] Univ Calif Los Angeles, Los Angeles, CA USA
[8] Mem Sloan Kettering Canc Ctr, New York, NY USA
[9] Hunstman Canc Inst, Salt Lake City, UT USA
[10] Harvard Med Sch, Dana Farber, Brigham & Womens Canc Ctr, Boston, MA USA
[11] UC San Francisco, San Francisco, CA USA
[12] Brigham & Womens Hosp, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2006
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study
    Fuereder, Thorsten
    Minichsdorfer, Christoph
    Mittlboeck, Martina
    Wagner, Christina
    Heller, Gerwin
    Putz, Eva M.
    Oberndorfer, Felicitas
    Mullauer, Leonhard
    Aretin, Marie-Bernadette
    Czerny, Christian
    Schwarz-Nemec, Ursula
    ORAL ONCOLOGY, 2022, 124
  • [42] A Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Endometrial Carcinoma
    Makker, Vicky
    Rasco, Drew
    Dutcus, Corina
    Stepan, Daniel
    Li, Di
    Schmidt, Emmett
    Shumaker, Robert
    Young, Louise
    Taylor, Matthew
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 152 - 153
  • [43] Phase II trial of combination pembrolizumab, olaparib, and temozolomide for patients with recurrent glioma
    Schaff, Lauren
    Fortunato, John
    Grommes, Christian
    Gavrilovic, Igor T.
    Lin, Andrew
    Pentsova, Elena
    Miller, Alex
    Newton, Adam
    Gonzalez, Ashley
    Mellinghoff, Ingo K.
    Kaley, Thomas Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
    Kelly, Ciara M.
    Qin, Li-Xuan
    Whiting, Karissa A.
    Richards, Allison L.
    Avutu, Viswatej
    Chan, Jason E.
    Chi, Ping
    Dickson, Mark A.
    Gounder, Mrinal M.
    Keohan, Mary Louise
    Movva, Sujana
    Nacev, Benjamin A.
    Rosenbaum, Evan
    Adamson, Travis
    Singer, Samuel
    Bartlett, Edmund K.
    Crago, Aimee M.
    Yoon, Sam S.
    Hwang, Sinchun
    Erinjeri, Joseph P.
    Antonescu, Cristina R.
    Tap, William D.
    D'Angelo, Sandra P.
    CLINICAL CANCER RESEARCH, 2023, 29 (11) : 2043 - 2051
  • [45] PHASE I/II TRIAL OF RADIOSURGERY PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT/PROGRESSIVE GLIOBLASTOMA - INITIAL REPORT
    Mohammadi, Alireza Mohammad
    Chao, Samuel T.
    Peereboom, David M.
    Barnett, Gene H.
    Suh, John H.
    Brewer, Cathy
    Vogelbaum, Michael A.
    NEURO-ONCOLOGY, 2012, 14 : 103 - 104
  • [46] A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma
    Sepulveda, J. M.
    Belda-Iniesta, C.
    Gil-Gil, M.
    Perez-Segura, P.
    Berrocal, A.
    Reynes, G.
    Gallego, O.
    Capellades, J.
    Ordonez, J. M.
    La Orden, B.
    Balana, C.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (09): : 743 - 750
  • [47] A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma
    J. M. Sepúlveda
    C. Belda-Iniesta
    M. Gil-Gil
    P. Pérez-Segura
    A. Berrocal
    G. Reynés
    O. Gallego
    J. Capellades
    J. M. Ordoñez
    B. La Orden
    C. Balañá
    Clinical and Translational Oncology, 2015, 17 : 743 - 750
  • [48] Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma
    Hunt, Jonathan T.
    Chambers, Laura M.
    Yao, Meng
    Joehlin-Price, Amy
    Debernardo, Robert
    Rose, Peter G.
    GYNECOLOGIC ONCOLOGY REPORTS, 2021, 37
  • [49] Phase II study of pembrolizumab and lenvatinib in platinum sensitive recurrent ovarian cancer
    Bauer, Smadar
    Saad, Akram
    Greenhouse, Inbal
    Rapoport, Anna Ruth
    Shahar, Shir
    Barnatan, Tania
    Satchi-Fainaro, Ronit
    Shapira-Frommer, Ronnie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Phase 2 Study of Pembrolizumab Plus CC-486 vs Pembrolizumab Plus Placebo in Previously Treated Patients with Advanced NSCLC
    Levy, B.
    Giaccone, G.
    Besse, B.
    Felip, E.
    Garassino, M.
    Domine, M.
    Garrido, P.
    Piperdi, B.
    Ponce Aix, S.
    Slepetis, R.
    Wu, X.
    Fandi, A.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1803 - S1804
12345